newsfilter
← Latest News
GlobeNewswire·

SCYNEXIS Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Completed Phase 1 study of SCY-770, a first-in-class, highly selective, oral direct AMPK activator for the treatment of ADPKD; Phase 2 proof-of-concept trial to initiate in Q4 2026Awarded BARDA contract providing up to